← Eichor
Condition: Cebpa Mutation Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cebpa Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06529250Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
Phase 1/Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07451912
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.